Collaborative Approaches to Lead Generation

Abstract:

Various phases of pharmaceutical research and development have seen examples of collaborative initiatives: codevelopment, marketing and acquisition. Lead generation is a key component of successful drug discovery. It is also the phase where the risks associated with drug discovery research are highest. A number of collaborative approaches to lead generation have emerged in recent years. The goal of Open Innovation Drug Discovery (OIDD) is to identify novel molecules that are active in relevant disease biology models that can serve as the foundation for collaborative work between Lilly and external investigators. In 2003, the National Institutes of Health (NIH) funded the Molecular Library Program (MLP) with the intent to generate early‐stage compounds that could be used by researchers for target validation and could subsequently be developed toward drug discovery. The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, nonprofit R&D organization aiming to deliver new treatments for neglected diseases.